0,1,2,3,4
Table 6.5.2: Randomised phase III controlled trials - first-line treatment of mCRPC,,,,
"Study
Intervention
Comparison
Selection criteria
Main outcomes",,,,
DOCETAXEL,,,,
"SWOG 99-16 
2004 [1200]","docetaxel/EMP, 
every 3 weeks, 
60 mg/m2, EMP 
3 x 280 mg/day","mitoxantrone, 
every 3 weeks, 
12 mg/m2 
prednisone 5 mg 
BID",,"OS: 17.52 vs. 15.6 mo. 
(p = 0.02, HR: 0.80; 
95% CI: 0.67-0.97) 
PFS: 6.3 vs. 3.2 mo. 
(p < 0.001)"
"TAX 327 
2004, 2008 
[1190,1201]","docetaxel, every 
3 weeks, 75 mg/m2 
prednisone 5 mg 
BID 
or 
docetaxel, weekly, 
30 mg/m2 
prednisone 5 mg 
BID","mitoxantrone, 
every 3 weeks, 
12 mg/m2, 
Prednisone 5 mg 
BID",,"OS: 19.2 for 3 weekly 
vs. 17.8 mo. 4-weekly 
and 16.3 in the control 
group. 
(p = 0.004, HR: 0.79, 
95% CI: 0.67-0.93)"
ABIRATERONE,,,,
"COU-AA-302 
2013, 2014, 2015 
[1182, 1183, 1202]","abiraterone + 
prednisone","placebo + 
prednisone","- No previous docetaxel. 
- ECOG 0-1. 
-  PSA or radiographic 
progression. 
- No or mild symptoms. 
- No visceral metastases.","OS: 34.7 vs. 30.3 mo. 
(HR: 0.81, p = 0.0033). 
FU: 49.2 mo. rPFS: 
16.5 vs. 8.3 mo. 
(p < 0.0001)"
ENZALUTAMIDE,,,,
"PREVAIL 
2014 [1185]",enzalutamide,placebo,"- No previous docetaxel. 
- ECOG 0-1. 
-  PSA or radiographic 
progression. 
- No or mild symptoms. 
- 10% had visceral mets.","OS: 32.4 vs. 30.2 mo. 
(p < 0.001). FU: 22 mo. 
(p < 0.001 HR: 0.71, 
95% CI: 0.60-0.84) 
rPFS: 20.0 mo. vs. 
5.4 mo. HR: 0.186 
(95% CI: 0.15-0.23) 
p < 0.0001)"
SIPULEUCEL-T,,,,
"IMPACT2010 
[1196]",sipuleucel-T,placebo,"-  Some with previous 
docetaxel. 
- ECOG 0-1. 
-  Asymptomatic or 
minimally symptomatic.","OS: 25.8 vs. 21.7 mo. 
(p = 0.03 HR: 0.78, 
95% CI: 0.61-0.98).  
FU: 34.1 mo. PFS: 
3.7 vs. 3.6 mo. (no 
difference)"
2006 [1203],sipuleucel-T,placebo,"- ECOG 0-1. 
- No visceral met. 
-  No corticosteroids.","OS: 25.9 vs. 21.4 mo. 
(p = 0.1). FU: 36 mo. 
PFS: 11.7 vs. 10.0 wk."
IPATASERTIB,,,,
"IPAtential150
2021 [1197]","ipatasertib 
(400 mg/d) + 
abiraterone 
(1000 mg/d) + 
prednisone  
(5 mg bid)","abiraterone + 
prednisolone + 
placebo","Previously untreated for 
mCRPC, asymptomatic/
mildly symptomatic, with 
and without PTEN loss 
by IHC","rPFS in PTEN loss 
(IHC) population:  
18.5 vs. 16.5 mo.  
(p = 0.0335, HR: 0.77 
95% CI: 0.61-0.98)"
PROpel [1198],"olaparib  
(300mg BID) +  
abiraterone 
(1000 mg/d) + 
prednisone  
(5 mg BID)","placebo + 
abiraterone + 
prednisone","- ECOG 0-1.
-  regardless of HRRm 
(retrospective testing).
-  prior taxane for 
mHSPC allowed.","HR: 0.66; 95% 
CI: 0.54â€“0.81;
(p = 0.001)"
